Recently developed vaccines and boosters have emerged as a shield against COVID-19. They activate the immune formula of the frame and induce the production of antibodies to neutralize the virus. Carefully planned booster doses of the vaccine act as boosters to aid defense of the opposite frame. to the virus. The extent of this defense, i. e. vaccine-induced immune activation, can be estimated by measuring the titer or concentration of antibodies circulating within the vaccinated person.
It has been warned that vulnerable teams could have reduced defense despite vaccination and boosters. To detect risk in the vaccinated elderly population, a team of researchers led by Professor Masanori Nakayama of the Research and Strategy Development Organization, Okayama University, and Dr. Hideharu Hagiya of Okayama University Graduate School of Medicine set out to assess the body’s immune reaction in elderly Japanese who had won their third dose of the vaccine.
Explaining the motivation behind their study, Professor Nakayama says that “despite vaccines, several elderly patients in Japan fall ill from epidemic outbreaks, some of which are critical. Therefore, we feel the need to investigate post-COVID-19 mRNA vaccine antibody titers in the elderly.
The team analyzed antibody titers against the virus that causes COVID-19, SARS-CoV-2, after the third booster vaccine administered. The study included 1,046 seniors from 23 other care facilities. Each player had won two doses of Moderna or Pfizer mRNA vaccine at least six months before the start of the study. A comparison of antibody titers between the elderly and the younger also provided greater clarity.
Most of the time, blood is drawn from the veins for titer analysis, which can be complicated and uncomfortable for older people. To solve this problem, researchers have developed a solution; They estimated antibody titers from blood drawn only from fingertips. They used the “Mokobio SARS-CoV-2 IgM immunoassay”
The effects revealed that the number and proportion of non-responders, i. e. those with antibody titers below 1000 U/mL at any time during control after vaccination, increased with age. Nearly 10% of participants had negligible antibody production despite receiving an additional dose of vaccine. In addition, among COVID-19 survivors in the groups tested, antibody titers measured after one month were particularly higher compared to those who received the third booster dose.
Further research showed that the proportion of responders (those with antibody titers greater than 1000 U/mL) decreased as the age of individuals increased from 70 to 90 years. human body. Other people apparently lose their ability to react to foreign bodies as they age, become sluggish, or don’t respond to vaccines. This explains why other older people are more vulnerable to infectious diseases.
These effects were published in the Journal of Infection.
As life struggles to return to normal throughout COVID-19, new methods continue to evolve globally from the virus. This study proposes a strategy of this type that maintains in the brain the long-term protection of older adults. Older adults in LTCF show a weaker reaction to booster mRNA vaccines and would possibly be obvious non-responders. Therefore, it is imperative to expand serological testing protocols targeting the elderly after vaccination for greater disease control.
Please indicate the appropriate maximum category to facilitate the processing of your request
Thank you for taking the time to provide feedback to the editors.
Your opinion is for us. However, we do not guarantee individual responses due to the large volume of messages.